/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

J

Jie Hu

Hebei Medical University(CN)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

234

Papers

8.9K

Citations

41

h-index

105

i10-index

Jie Hu is an academic researcher from Hebei Medical University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Hepatocellular Carcinoma Treatment and Prognosis & Cancer Immunotherapy and Biomarkers. The author has an h-index of 41, co-authored 199 publications.

ORCID: 0000-0003-3518-6477

Research Topics

Lung Cancer Treatments and Mutations Hepatocellular Carcinoma Treatment and Prognosis Cancer Immunotherapy and Biomarkers MicroRNA in disease regulation Cancer Genomics and Diagnostics

Papers by this author

works

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

2019 · The Lancet · 2,108 citations

https://doi.org/10.1016/s0140-6736(19)32222-6

Luis Paz‐Ares Mikhail Dvorkin Yuanbin Chen Niels Reinmuth

Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis

2020 · Critical Care · 77 citations

https://doi.org/10.1186/s13054-020-03340-4

Chaomin Wu Dongni Hou Chunling Du Yanping Cai

MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET–SOCS1–MMP9 signaling axis

2017 · Cell Death and Disease · 70 citations

https://doi.org/10.1038/cddis.2017.142

Qing Chen Dan Yin Yong Zhang Lei Yu

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407

2021 · JTO Clinical and Research Reports · 51 citations

https://doi.org/10.1016/j.jtocrr.2021.100225

Ying Cheng Li Zhang Jie Hu Donglin Wang

Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway

2019 · Journal of Experimental & Clinical Cancer Research · 40 citations

https://doi.org/10.1186/s13046-019-1057-7

Jian Zhou Guimei Qu Ge Zhang Zuoren Wu

The neutrophil-to-lymphocyte ratio is a predictive factor for the survival of patients with hepatocellular carcinoma undergoing transarterial chemoembolization

2020 · Annals of Translational Medicine · 31 citations

https://doi.org/10.21037/atm.2020.02.113

Chengguo Wang Mengmeng Wang Xiangnan Zhang Shoujie Zhao

Research topics

topics

Lung Cancer Treatments and Mutations

Hepatocellular Carcinoma Treatment and Prognosis

Cancer Immunotherapy and Biomarkers

MicroRNA in disease regulation

Cancer Genomics and Diagnostics

Chat about Author

Papers

Chat

Click to start Chat